Outcome Bonds: Let Wall Street Pay for the Cure

The thesis

A curative gene therapy can cost $2M once yet save far more over a lifetime — and still be rejected, because a payer's budget is annual and patients switch plans. Our financing model punishes cures for being one-time. That is an accounting failure masquerading as an affordability problem.

Borrow from finance

Treat a cure like a house: amortise it. An outcome-linked bond fronts the cost; the payer pays it down over years — but only while the patient remains well. If the therapy fails, the coupon stops. Risk moves to capital markets that are built to price and hold it.

Why every party wins

• Patients get access to cures instead of being told to wait.
• Payers convert a budget-busting lump sum into a manageable, outcome-contingent stream.
• Manufacturers get paid for value delivered, with skin in the game on durability.
• Investors get a new, health-correlated asset class.

The rails needed

A neutral outcomes registry (durable, auditable, privacy-preserving) that both sides trust to say whether the patient is still well. That measurement layer is the whole game.

Provocation

We solved "expensive one-time asset, long-term value" for houses and infrastructure a century ago. Applying the same financial engineering to cures is not exotic — it is overdue.

A first-principles provocation from the Anxya Health Futures desk. Directional and informational — not medical, legal, financial or regulatory advice. The point is to move the debate, then do the hard validation work.